Explore the vast range of titles available.

Biblical Scholars working with ancient texts are engaged in the daily task of Bible translation. A commitment to Biblical Performance Criticism (BPC) can be transformative in the task of translation. It is argued in this paper that responsible translation will work towards replicating the artistry of original transmitters of texts in order to draw out traces of the original orality embedded in the texts. Examples of performance-sensitive translations of texts predominantly from the Hebrew Bible are provided. This e-paper also demonstrates that translations that draw out performative elements contribute to interpretation, especially when such scripts are staged before audiences. Subsequent analysis of the performance including audience response contributes to such interpretation. Performance-sensitive translation and actual performance thus become tools for embodiment and the interpretation of biblical texts in our own time.

All biblical scholars are committed to the interpretation of ancient written texts, but Biblical Performance Criticism (BPC) reminds interpreters that performance helps us better understand Scripture. A distinct difference between Narrative Criticism and Performance Criticism is the broader application of Performance Criticism to poetic and prose texts that are not grounded in narrative. The ambiguity of prose and poetry that does not readily identify speakers is open to a range of performative interpretations. Furthermore, audiences are necessary for performance and contribute to meaning-making. The embodied experience of performers and audience alike contribute to the interpretation of biblical texts. This article reflects on a performance of Ecclesiastes translated as a script of a television talk show, claiming that embodying and performing Scripture is itself a method for interpretation. Through the performance of Scripture, we are reminded that interpretation is shared and dynamic within the community of faith.

Xylazine exacerbates the respiratory depression induced by fentanyl. Because xylazine is a non-opioid, it is resistant to reversal by opioid receptor antagonists such as naloxone (e.g., Narcan ), thereby complicating attempts at treatment of fentanyl overdose. Antagonists of large-conductance potassium BK (big potassium) channels (BK ) in the carotid bodies reverse drug-induced hypoxia (decreased pO ) and hypercapnia (increased pCO ). In animals and human volunteers, the selective BK antagonist ENA-001 reverses the respiratory depression induced by opioids and non-opioids, i.e., it is an \"agnostic\" respiratory reversal agent. Given the seriousness of xylazine plus fentanyl combination (XFC) overdose, the present pilot study in rats was designed to evaluate the potential of a single intravenous bolus of ENA-001 to mitigate the acute respiratory depression induced by a prior intravenous bolus infusion of an XFC. XFC-induced respiratory depression was manifested as a decrease in pO and an increase in pCO . ENA-001, but not the vehicle, rapidly reversed these XFC-induced changes. Based on the results of this pilot study, the \"agnostic\" nature of ENA-001 respiratory stimulation appears to extend to XFC-induced overdose. Given the urgent clinical need, additional study seems warranted.

Could it be possible that we should give some weight to the contribution of biological differences as contributors to the greater fentanyl mortality in males than in females? Most current explanations for a sex difference are based largely on psychosocial and other non-physiologic contributions. Our recent findings suggest a biological contribution. This could have broad implications for the interpretation and prevention of fentanyl overdose deaths.

Background ENA-001 (formerly known as GAL-021) is a novel, first-in-class respiratory stimulant. Pharmacokinetic and pharmacodynamic properties, plus safety and tolerability, were assessed in a randomized, single-center study of healthy volunteers. Methodology This four-period study was designed to test continuous two-hour intravenous infusion regimens of ENA-001 at doses of 0.96, 1.44, and 1.92 mg/kg/hour versus placebo. Each participant received four infusions with a seven-day minimum washout between them: one infusion each of the three doses of ENA-001 and one placebo. Pharmacokinetic and pharmacodynamic parameters were assessed and adverse events were recorded. Results A total of 17 participants completed the study. ENA-001 was generally safe and well tolerated over the dose range studied (0.96 to 1.92 mg/kg/hour). ENA-001 was able to drive hyperventilation in a dose-dependent manner in healthy participants. Increases in ventilation due to ENA-001 were not associated with like-magnitude blood pressure response. ENA-001-stimulated decreases in ETCO were associated with small, statistically significant, increases in SpO levels. Hyperventilation occurred in two participants at the highest dose level, leading to study discontinuation. The terminal half-life of ENA-001 was 6.33 hours. Conclusions The respiratory stimulant ENA-001 demonstrated well-behaved pharmacokinetics following the two-hour infusion. Mean peak plasma concentrations and the mean total systemic exposure values were approximately dose-proportional in the dose range studied.

In the mid-1980s, emerging from a conservative evangelical upbringing that valued Christian otherworldliness above the concrete reality of lived experience, I wrote a small treatise defending the importance of the land for the people of the Hebrew Bible. It focused specifically on the community addressed by Deuteronomy whose land was theirnaḥălâ, their “inheritance,” terminology that evoked the idea of the divine giver as a loving father. Even at that time, I was not insensible to the irony of a people receiving with gratitude a land that was already occupied by others, but my analysis nevertheless paid attention to the

Rationale Reports of cognitive decline, particularly in the domains of executive functions (EFs), are common among menopausal women. Objective This study aims to determine the impact of the psychostimulant lisdexamfetamine (LDX) on subjective and objective cognitive function among menopausal women who report new-onset EF complaints. Methods Thirty-two healthy perimenopausal and early postmenopausal women experiencing mid-life-onset executive function difficulties as measured using the Brown Attention Deficit Disorder Scale (BADDS) were administered LDX 40–60 mg/day for 4 weeks in this double-blind, placebo-controlled, cross-over study. Diagnosis of lifetime ADHD was exclusionary. BADDS total and subscale scores and performance on verbal memory and working memory tasks were outcomes of interest. Results Analyses revealed a significant effect of LDX treatment over placebo for total BADDS scores ( p  = 0.0001) and for four out of the five BADDS subscales (all p  < 0.004). LDX treatment also resulted in significant improvement in delayed paragraph recall ( p  = 0.018), but there was no significant effect of treatment on other cognitive measures. Systolic blood pressure ( p  = 0.017) and heart rate increased significantly ( p  = 0.006) when women were on LDX but remained, on average, within the normal range. Conclusions LDX 40–60 mg/day was well tolerated and improved the subjective measures of executive function as well as objective measures of delayed verbal recall in this sample of healthy menopausal women.

Research reviewing health records of elderly residents. [(BNI unique abstract)] 17 references

This valuable book reviews and discusses the latest research on family sexual abuse. With contributions by both practitioners and researchers, it covers such issues as sibling incest; the background of sexual offenders; effects of sexual abuse on children, of offender removal from the home and of reunification and the prognosis for incest offenders after treatment. Within this context the immediate problems of local practitioners dealing with real life instances are highlighted and discussed.